in life when bone catabolism supersedes anabolism, the significant loss of bone mass (osteoporosis) becomes a common medical problem (Riggs and Melton, 1986). mal cells are differentiated along the osteoblastic lincell lines were available from four unrelated families. We employed RT-PCR to amplify and sequence the coding eage in vitro. We show that LRP5 is able to mediate Wnt region of the LRP5 cDNA in the patients from these signaling in vitro via the canonical pathway and that families, and we identified putative disease-causing mudominant-negative forms of LRP5 can interfere with this tations in each sample (Figure 2A ). We confirmed that process. Lastly, we show that dominant-negative forms the mutations were homozygous and inherited by using of LRP5 can affect bone thickness in mouse calvarial the patients' and their parents' genomic DNA. We then explant cultures. These data indicate that LRP5 affects began performing an exon-by-exon search for diseasethe accrual of bone mass during Wnt-mediated osteocausing mutations in the remaining families. To date, blastic proliferation and differentiation.
Summary
In contrast to other heritable childhood disorders that affect bone strength, patients with OPPG do not have In humans, low peak bone mass is a significant risk identifiable defects in collagen synthesis, anabolic and factor for osteoporosis. We report that LRP5, encoding catabolic hormones, calcium homeostasis, endochonthe low-density lipoprotein receptor-related protein 5, dral growth, or bone turnover (Gong et al., 1996) . Histoaffects bone mass accrual during growth. Mutations logical analyses of bone biopsies from affected patients in LRP5 cause the autosomal recessive disorder osreveal deficient trabecular bone volume (Figures 1D and teoporosis-pseudoglioma syndrome (OPPG). We find 1E) but normal surface density and appearance of osteothat OPPG carriers have reduced bone mass when blasts and osteoclasts on bone surfaces (data not compared to age-and gender-matched controls. We shown). Intriguingly, obligate carriers of OPPG mutations (i.e., parents of affected children) have been sugdemonstrate LRP5 expression by osteoblasts in situ gested to have an increased incidence of osteoporosisand show that LRP5 can transduce Wnt signaling in related fractures. In addition to the skeletal phenotype, vitro via the canonical pathway. We further show that individuals with OPPG have eye involvement ( Figure 1C ). a mutant-secreted form of LRP5 can reduce bone Many patients with OPPG are born with severe disrupthickness in mouse calvarial explant cultures. These tion of ocular structure, phthisis bulbi. However, persisdata indicate that Wnt-mediated signaling via LRP5 tent hyperplasia of the primary vitreous (PHPV) has been affects bone accrual during growth and is important observed in children with milder eye involvement, leadfor the establishment of peak bone mass.
ing to speculation that ocular pathology results from failed regression of the primary vitreal vasculature durIntroduction ing fetal growth. Using the positional candidate approach, we have In humans, bone mass increases during growth and identified the gene responsible for OPPG as being the peaks by the third decade of life (Lu et al., 1996) . Later LDL receptor-related family member LRP5. We show that obligate carriers of mutant LRP5 genes have reduced bone mass when compared to age-and gender- pattern changes over time when pluripotent mesenchy- (D and E) Iliac crest bone biopsies (both at 40ϫ magnification) from an unaffected 2.5-year-old child (control) and from a 2.5-year-old child with OPPG, respectively. The control biopsy is substantially thicker than the OPPG biopsy. Note that the bone volume in the control (D) allows for only one cortical surface and a substantial trabecular bone network to be contained within the microscopic field. In contrast, both the inner and outer cortices and very little trabecular bone are contained within the field of the OPPG patient (E). mal cells are differentiated along the osteoblastic lincell lines were available from four unrelated families. We employed RT-PCR to amplify and sequence the coding eage in vitro. We show that LRP5 is able to mediate Wnt region of the LRP5 cDNA in the patients from these signaling in vitro via the canonical pathway and that families, and we identified putative disease-causing mudominant-negative forms of LRP5 can interfere with this tations in each sample ( Figure 2A ). We confirmed that process. Lastly, we show that dominant-negative forms the mutations were homozygous and inherited by using of LRP5 can affect bone thickness in mouse calvarial the patients' and their parents' genomic DNA. We then explant cultures. These data indicate that LRP5 affects began performing an exon-by-exon search for diseasethe accrual of bone mass during Wnt-mediated osteocausing mutations in the remaining families. To date, blastic proliferation and differentiation.
we have identified a total of six different homozygous frameshift or nonsense mutations in affected offspring Results from consanguineous families (Figure 2A ). We have also found homozygous missense mutations in affected paMutations in LRP5 Cause OPPG tients from two other consanguineous families and hetTwenty-eight families affected by OPPG participated in erozygous nonsense, frameshift, and missense mutathis study. The genetic mapping of OPPG has been tions in affected patients from four nonconsanguineous described (Gong et al., 1996) . We found that genomic families ( Figure 2A 
Lrp5 Is Expressed by Osteoblasts
We performed in situ hybridization on skeletal elements in developing mice to determine possible sites of action of Lrp5 during bone formation. The lateral half of the mouse clavicle ossifies by membranous ossification be- However, BMP2 addition causes a significant increase in Lrp5 and Lrp6 expression by 48 hr. This increased via a dominant-negative mechanism. Given the similarity in phenotype among patients with OPPG, we speculate expression persists after other markers of osteoblastic differentiation (Alpl, Col1a1, and Bglap) have diminthat OPPG disease-causing alleles are loss-of-function. However, we were able to create an artificial LRP5 conished. It is interesting that the increased Lrp5 expression occurs in cells that are beginning to express the more struct that lacks the transmembrane domain (LRP5⌬TM) and could be secreted (Figures 2A and 2B ). This indidifferentiated osteoblastic phenotype. Since cells are Tamai 
tant, both LRP5⌬C-ST2 and LRP5-ST2 cells were able
Conditioned Media Containing the DominantNegative Secreted Form of LRP5 Reduces to increase ALP activity, indicating that the ␤-catenin pathway is still functioning and that LRP5⌬C inhibitory Bone Accrual in Calvarial Explant Cultures While pluripotent mesenchymal cell lines can be inactivity is upstream in this pathway ( Figure 6D ). Finally, when we measured Smad1 transcriptional activity by duced into the osteoblastic lineage, they may not reflect endogenous osteoblastic proliferation and differentiausing a GalSmad1-based one-hybrid assay, we found that LRP5⌬C-ST2 cells and LRP5-ST2 cells responded tion. Consequently, we sought to determine whether the secreted form of LRP5 (LRP5⌬TM) could interfere with almost identically to the stimulation of BMP2 ( Figure  6E) . Therefore, the inability of LRP5⌬C-ST2 cells to rebone accrual in calvarial explant cultures. In three independent experiments, explants that were cultured in the spond to BMP2 is not due to an alteration in the BMP2 signaling pathway. Altogether our data suggest that the presence of conditioned media from cells expressing LRP5⌬TM consistently had thinner bone, as determined integrity of Wnt/LRP5 signaling is necessary for the induction of alkaline phosphatase in these cells.
by ALP staining and von Kossa staining, than did ex- VRNI via different mechanisms of mutational effect.
Statistically significant differences between the study groups' mean z scores and control means (z ϭ 0) were determined using Student's t test. 
LRP5 Loss-of-Function Mutations

